A new prescription wearable device delivers targeted vibration therapy to the spine and hips, slowing bone density loss by 85% in the spine and 55% in the hips for postmenopausal women with early bone loss. The FDA-cleared technology, inspired by NASA research, represents a significant shift in how doctors approach bone health, moving from waiting until osteoporosis develops to intervening earlier when bone loss first appears .

Why Doctors Are Excited About Treating Bone Loss Before It Becomes Osteoporosis?

For years, physicians faced a frustrating gap in bone health treatment. Women diagnosed with osteopenia, the precursor to osteoporosis, had few options beyond the standard advice: take calcium, get vitamin D, and exercise. No medications were approved specifically for osteopenia, leaving doctors unable to offer meaningful intervention to patients who wanted to prevent the disease from progressing .

"For years, when a patient with osteopenia asked what they could do beyond calcium, vitamin D, and exercise, we didn't have much to offer. Many of the women I treat are younger peri- and post-menopausal women who have osteopenia, and want to do everything they can to prevent developing osteoporosis, in order to stay strong enough to travel, exercise, and lift their grandchildren. But there are no approved drug therapies for osteopenia. This gap between diagnosis and drug therapy has been frustrating," said David B. Karpf, an endocrinologist and attending physician in the Osteoporosis and Metabolic Bone Disease Clinic at Stanford University School of Medicine.

David B. Karpf, Endocrinologist and Attending Physician, Stanford University School of Medicine

This treatment gap matters because nearly 10 million Americans have osteoporosis, and another 44 million live with low bone density. The condition develops silently over many years, making early intervention critical, especially during menopause when bone loss accelerates rapidly .

How Does the Vibration Therapy Device Work?

The device, called Osteoboost, is worn low around the hips and over the sacrum, delivering low-magnitude, precisely calibrated vibration therapy directly to the lumbar spine and hips, the regions most vulnerable to fracture. The treatment was inspired by NASA-funded research and was proven in a gold-standard, double-blinded clinical trial conducted at the University of Nebraska Medical Center .

In the clinical trial, participants who used the device three or more times per week for 30-minute sessions over a 12-month period showed significant improvements in bone density. The results were substantial: spine bone density loss slowed by 85%, while hip bone density loss slowed by 55%. These outcomes represent a meaningful difference for women trying to prevent fractures and maintain independence as they age .

The device received FDA Breakthrough Device designation in 2024 and was cleared through the De Novo pathway, a regulatory process reserved for novel medical devices. Since devices began shipping in May 2025, more than 2,500 physicians have prescribed Osteoboost, including clinical professionals at more than 30 leading academic medical centers. The device was named to TIME's 2025 list of Best Inventions .

Steps to Supporting Bone Health During and After Menopause

• Get a bone density screening: Women entering menopause should discuss bone density testing with their doctor, as early detection of low bone density allows for earlier intervention before osteoporosis develops.
• Combine multiple approaches: Bone health requires more than one strategy; calcium, vitamin D, exercise, and newer treatments like vibration therapy work together to slow bone loss and maintain strength.
• Prioritize vitamin D status: Vitamin D is essential for calcium absorption and muscle function, with research showing that correcting low vitamin D levels increases lower-extremity strength and balance, reducing fall risk in older adults .
• Engage in resistance and weight-bearing exercise: Physical activity that challenges bones and muscles is foundational to bone health, and working with a physical therapist can help ensure proper form and progression.
• Discuss all available options with your doctor: Treatment options now extend beyond supplements and medications to include non-drug devices, allowing for personalized approaches based on individual risk factors and preferences.

What Role Does Vitamin D Play in Bone and Muscle Health?

While the Osteoboost device represents innovation in bone density treatment, the foundation of bone health still rests on basic nutrients. Vitamin D plays a critical role that extends beyond bone strength alone. It acts more like a hormone than a typical nutrient, regulating calcium and phosphorus levels throughout the body. Without adequate vitamin D, the body cannot effectively absorb and use the calcium you consume, even if your diet is rich in calcium sources .

Low vitamin D levels are associated with lower bone mineral density, higher risk of stress fractures, and increased fracture risk in older adults. But vitamin D's impact goes further. Research shows that deficiency is also linked to reduced muscle strength, slower muscle contraction, and higher fall risk, particularly in older adults. Several studies have demonstrated that correcting low vitamin D levels increases lower-extremity strength and balance, which is especially relevant for patients trying to improve their gait and reduce their risk of falls .

For most adults, 800 to 2,000 IU (International Units) of vitamin D per day is commonly recommended for maintenance, though many people need 1,000 to 2,000 IU daily to maintain sufficient blood levels. If blood levels are low, healthcare providers may recommend up to 2,000 to 4,000 IU per day or short-term higher doses under medical supervision. Vitamin D is fat-soluble, meaning it absorbs best when taken with a meal that contains fat .

Vitamin D status is measured with a blood test called 25-hydroxyvitamin D. In the United States, general reference ranges are as follows: deficient (below 20 ng/mL), insufficient (20 to 29 ng/mL), and sufficient (30 to 50 ng/mL). Many experts agree that levels below 30 ng/mL are suboptimal for musculoskeletal health, particularly in people with pain, injuries, or fracture risk .

Why Is Funding for Women's Bone Health Innovation Still Lagging?

Despite the prevalence of bone loss in women, women's health remains dramatically underfunded relative to the scale of need. A January 2026 World Economic Forum report found that the women's health sector receives just 6% of private healthcare capital, with most funding concentrated in reproductive health, maternal care, and women's oncology. Venture capital has historically favored software and artificial intelligence over regulated medical devices, even as populations age rapidly .

This funding gap has real consequences. The World Health Organization projects that by 2030, one in six people worldwide will be aged 60 or older, increasing demand for solutions that support strength, mobility, and independence for seniors. Half of women over 50 will experience a fracture due to bone loss, yet osteoporosis remains dramatically underdiagnosed and undertreated. Recent funding rounds, including an $8 million investment in Osteoboost, signal growing recognition that bone health innovation deserves greater attention and resources .

The availability of non-drug treatment options like Osteoboost fills a critical gap in the treatment landscape. For women with osteopenia who want to take action before osteoporosis develops, and for those who prefer alternatives to pharmaceutical approaches, having clinically supported options changes the trajectory of bone health management. As more physicians adopt these tools and more research validates their effectiveness, the standard of care for bone health is shifting from reactive treatment to proactive prevention .